Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 391.57M | 387.32M | 405.87M | 473.15M | 549.91M |
| Total Receivables | 3.09M | 3.16M | 3.05M | 2.06M | 2.75M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 43.48M | 20.04M | 22.10M | 16.92M | 17.15M |
| Total Current Assets | 438.14M | 410.52M | 431.02M | 492.13M | 569.81M |
|
|
|||||
| Total Current Assets | 438.14M | 410.52M | 431.02M | 492.13M | 569.81M |
| Net Property, Plant & Equipment | 120.17M | 120.31M | 124.67M | 125.12M | 121.45M |
| Long-term Investments | 52.06M | 52.75M | 60.52M | 801.00K | 801.00K |
| Goodwill | 52.06M | 52.75M | 60.52M | 801.00K | 801.00K |
| Total Other Intangibles | 36.44M | 39.46M | 42.76M | 1.32M | 1.31M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.89M | 7.78M | 7.74M | 8.00M | 7.92M |
| Total Assets | 653.70M | 630.83M | 666.70M | 627.37M | 701.29M |
|
|
|||||
| Total Accounts Payable | 3.95M | 4.27M | 2.09M | 4.25M | 4.59M |
| Total Accrued Expenses | 41.76M | 17.58M | 32.87M | 25.04M | 30.29M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 6.16M | 6.05M | 5.90M | 5.10M | 6.05M |
| Total Finance Division Other Current Liabilities | 41.30M | 66.23M | 73.11M | 57.76M | 59.35M |
| Total Other Current Liabilities | 41.30M | 66.23M | 73.11M | 57.76M | 59.35M |
| Total Current Liabilities | 93.17M | 94.12M | 113.96M | 92.15M | 100.27M |
|
|
|||||
| Total Current Liabilities | 93.17M | 94.12M | 113.96M | 92.15M | 100.27M |
| Long-Term Debt | 1.10M | 1.13M | 1.16M | 1.18M | 536.00K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 43.41M | 44.30M | 45.85M | 46.77M | 44.42M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 52.58M | 53.31M | 36.77M | 57.09M | 70.26M |
| Total Liabilities | 190.26M | 192.86M | 197.74M | 197.19M | 215.48M |
|
|
|||||
| Common Stock & APIC | 1.43B | 1.31B | 1.25B | 1.14B | 1.13B |
| Retained Earnings | -967.62M | -874.63M | -781.61M | -704.88M | -639.56M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 463.44M | 437.97M | 468.96M | 430.18M | 485.81M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 463.44M | 437.97M | 468.96M | 430.18M | 485.81M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 463.44M | 437.97M | 468.96M | 430.18M | 485.81M |
|
|
|||||